IVHD-valtrateCAS# 28325-56-6 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 28325-56-6 | SDF | Download SDF |
| PubChem ID | 45273108 | Appearance | Oil |
| Formula | C27H40O11 | M.Wt | 540.60 |
| Type of Compound | Iridoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(1S,4aR,6S,7R,7aS)-6-acetyloxy-4a-hydroxy-1-(3-methylbutanoyloxy)spiro[1,5,6,7a-tetrahydrocyclopenta[c]pyran-7,2'-oxirane]-4-yl]methyl 3-methyl-2-(3-methylbutanoyloxy)butanoate | ||
| SMILES | CC(C)CC(=O)OC1C2C(CC(C23CO3)OC(=O)C)(C(=CO1)COC(=O)C(C(C)C)OC(=O)CC(C)C)O | ||
| Standard InChIKey | QPMVBTMUWDUUTJ-KZYULCMASA-N | ||
| Standard InChI | InChI=1S/C27H40O11/c1-14(2)8-20(29)37-22(16(5)6)24(31)33-11-18-12-34-25(38-21(30)9-15(3)4)23-26(18,32)10-19(36-17(7)28)27(23)13-35-27/h12,14-16,19,22-23,25,32H,8-11,13H2,1-7H3/t19-,22?,23-,25-,26-,27+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. VHD-valtrate has anticancer effects against human ovarian cancer cells in vitro and in vivo, it is a potential therapeutic agent for ovarian cancer, providing a basis for development of the compound as a novel chemotherapeutic agent. |
| Targets | p53 | p21 | Bcl-2/Bax | Mdm2 | PARP | Caspase |
IVHD-valtrate Dilution Calculator
IVHD-valtrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8498 mL | 9.249 mL | 18.498 mL | 36.9959 mL | 46.2449 mL |
| 5 mM | 0.37 mL | 1.8498 mL | 3.6996 mL | 7.3992 mL | 9.249 mL |
| 10 mM | 0.185 mL | 0.9249 mL | 1.8498 mL | 3.6996 mL | 4.6245 mL |
| 50 mM | 0.037 mL | 0.185 mL | 0.37 mL | 0.7399 mL | 0.9249 mL |
| 100 mM | 0.0185 mL | 0.0925 mL | 0.185 mL | 0.37 mL | 0.4624 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- sn-Glycero-3-phosphocholine
Catalog No.:BCC4168
CAS No.:28319-77-9
- 11beta-Hydroxycedrelone
Catalog No.:BCN5179
CAS No.:283174-18-5
- Rucaparib (free base)
Catalog No.:BCC4012
CAS No.:283173-50-2
- Fmoc-ß-HoAsn(Trt)-OH
Catalog No.:BCC3228
CAS No.:283160-20-3
- Valifenalate
Catalog No.:BCC8071
CAS No.:283159-90-0
- 5-Hydroxy-1-tetralone
Catalog No.:BCN8397
CAS No.:28315-93-7
- Daurinoline
Catalog No.:BCN2742
CAS No.:2831-75-6
- Beta-Elemonic acid
Catalog No.:BCN2981
CAS No.:28282-25-9
- Baicalein 6-O-glucoside
Catalog No.:BCN3325
CAS No.:28279-72-3
- Tyrphostin A1
Catalog No.:BCC5404
CAS No.:2826-26-8
- Reynosin
Catalog No.:BCN5178
CAS No.:28254-53-7
- HOOBt
Catalog No.:BCC2817
CAS No.:28230-32-2
- 6-Ethoxydihydrosanguinarine
Catalog No.:BCN7589
CAS No.:28342-31-6
- Oxychelerythrine
Catalog No.:BCN4864
CAS No.:28342-33-8
- Canolol
Catalog No.:BCC8371
CAS No.:28343-22-8
- Mahanine
Catalog No.:BCN3176
CAS No.:28360-49-8
- Chrysin 6-C-glucoside
Catalog No.:BCN3324
CAS No.:28368-57-2
- Aloin B
Catalog No.:BCN2576
CAS No.:28371-16-6
- 7-Neohesperidosides
Catalog No.:BCN8200
CAS No.:28383-41-7
- Bumetanide
Catalog No.:BCC1119
CAS No.:28395-03-1
- 1(10)-Aristolen-2-one
Catalog No.:BCN7634
CAS No.:28398-06-3
- FR 236924
Catalog No.:BCC7564
CAS No.:28399-31-7
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- DR 2313
Catalog No.:BCC2451
CAS No.:284028-90-6
Valeriana jatamansi constituent IVHD-valtrate as a novel therapeutic agent to human ovarian cancer: in vitro and in vivo activities and mechanisms.[Pubmed:23597199]
Curr Cancer Drug Targets. 2013 May;13(4):472-83.
Identification of novel chemotherapeutic agents from traditional medicines and elucidation of the molecular basis of their anticancer effects are critical and urgently needed for modern pharmacotherapy. We previously found that analogs of the compounds present in Valeriana jatamansi, a traditional medicine used to treat mental disorders, possess notable antitumor properties; however, the underlying molecular mechanisms have not been fully demonstrated. In this study, we evaluated the anticancer effects of IVHD-valtrate, one of the most active Valeriana jatamansi derivatives, against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate inhibited the growth and proliferation of the A2780 and OVCAR-3 ovarian cancer cell lines in a concentration-dependent manner, while relatively low cytotoxicity to immortalized non-tumorigenic human ovarian surface epithelial cells (IOSE-144) was observed. Treatment with IVHD-valtrate arrested the ovarian cancer cells in the G2/M phase and induced apoptosis, and significantly suppressed the growth of A2780 and OVCAR3 xenograft tumors in a dose-dependent manner. The detailed in vitro and in vivo study on the molecular mechanisms of this compound demonstrated that IVHD-valtrate exposure modulated the expression of numerous molecules involved in cell cycle progression and apoptosis regardless of p53 status, leading to increase the level of p53, Rb, p21, p27 and decrease Mdm2, E2F1, Cyclin B1, Cdc25C and Cdc2. It also down-regulated Bcl-2/Bax and Bcl-2/Bad ratio and enhanced the cleavage of PARP and Caspases. Our preclinical results indicated IVHD-valtrate is a potential therapeutic agent for ovarian cancer, providing a basis for development of the compound as a novel chemotherapeutic agent.
A new iridoid tetraester from Valeriana jatamansi.[Pubmed:16724553]
Pharmazie. 2006 May;61(5):486-8.
A new iridoid tetraester, namely valeriotetrate A was isolated from the roots of Valeriana jatamansi Jones, together with the known iridoids IVHD-valtrate and valerosidate.
